Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo

Executive Summary

The move follows a similar price cut for Amgen's competing PCSK9 inhibitor Repatha and comes as PBMs, including UnitedHealth Group's OptumRx, are looking for ways to maintain the drug rebate status quo.

Advertisement

Related Content

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up
No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor
Amgen Explains How Big A Hit It May Take From Biosimilars, Pricing Pressures
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel